Orchestra BioMed (NASDAQ:OBIO – Get Free Report) and Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Profitability
This table compares Orchestra BioMed and Biorestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orchestra BioMed | -166.96% | -157.46% | -60.18% |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Orchestra BioMed and Biorestorative Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orchestra BioMed | 1 | 1 | 5 | 0 | 2.57 |
| Biorestorative Therapies | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
Orchestra BioMed has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
Insider & Institutional Ownership
53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Orchestra BioMed and Biorestorative Therapies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orchestra BioMed | $33.48 million | 6.58 | -$52.70 million | ($0.97) | -3.79 |
| Biorestorative Therapies | $360,000.00 | 23.65 | -$14.24 million | ($1.07) | -0.31 |
Biorestorative Therapies has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Summary
Orchestra BioMed beats Biorestorative Therapies on 8 of the 14 factors compared between the two stocks.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
